<DOC>
	<DOCNO>NCT02707055</DOCNO>
	<brief_summary>Background : Hormones naturally occur chemical body . Ghrelin hormone stimulate appetite . It may also stimulate alcohol craving use . Researchers want learn alcohol craving test drug block ghrelin lower alcohol craving . Objective : To test drug PF-05190457 decrease alcohol craving . Eligibility : People age 18 65 : Alcohol use disorder No serious medical problem Woman must postmenopausal surgery prevent pregnancy . Design : Participants stay inpatient unit Clinical Center two 2-week stage , separate least 2 day . The inpatient phase include : Taking study drug placebo mouth twice daily Blood test Tasting several sweet solution Physical exam Smokers smoke cigarette device give information smoke cigarette . Exposure alcohol , water , food cue bar-like room . Participants answer question computer . Blood pressure heart rate monitor arm cuff sensor chest . Saliva collect cotton roll mouth . MRIs : Participants lie table slide cylinder , coil place head . They complete task computer screen cylinder . This last 2 hour . Wearing virtual reality headset , walk around virtual room , select virtual food drink . Participants 8 hour long follow-up visit Outpatient Clinic These include : Counseling abstain alcohol use . Sessions may videotape . Physical exam</brief_summary>
	<brief_title>A Novel Compound Alcoholism Treatment : A Translational Strategy</brief_title>
	<detailed_description>Objective : Ghrelin 28-amino acid peptide stimulate appetite food intake . It endogenous ligand growth hormone secretagogue receptor ( GHSR1a ) . Preclinical study suggest ghrelin modulates alcohol reward processing . Previous work research team , indicate intravenous ( IV ) ghrelin administration , compare placebo , result acute increase alcohol crave cue-reactivity experiment alcoholic individual . Therefore , oral bioavailable , ghrelin receptor antagonist able pas blood brain barrier hold particular promise treatment alcohol use disorder ( AUD ) . This protocol part grant project fund National Center Advancing Translational Sciences ( NCATS ) aim generate preliminary evidence AUD safety efficacy ghrelin receptor ( GHSR1a ) antagonist , PF-05190457 , exist molecule available NIH-Industry Pilot Program NCATS . Completed preclinical clinical ( Protocol # 14-AA-0042 ) work demonstrate safety PF-05190457/alcohol interaction . The goal protocol conduct proof-of-concept human laboratory study ass early-signal efficacy PF-05190457 AUD . Study population : The study population AUD individual ( n = 55 ) . Study Design : A within-subject , counterbalanced , double-blind , placebo-controlled study . Outcome measure : The primary aim determine whether PF-05190457 , compare placebo , reduce alcohol cue-elicited craving . The main secondary aim determine whether PF-05190457 , compare placebo , reduces brain blood oxygen level dependent ( BOLD ) response exposure alcohol cue , task-based fMRI scan . We also investigate effect PF-05190457 food crave well food choice use virtual buffet experimental procedure . All outcome assess inpatient Unit NIH CC . After inpatient portion protocol , patient followed-up outpatient . During outpatient phase , patient offer motivational interviewing video feedback explore effect intervention , compare supportive counseling , maintain motivation alcohol abstinence inform future study medication like PF-05190457 behavioral treatment may combine . The outpatient phase optional treatment seek nontreatment seek participant .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female individual 1865 year old ( inclusive ) Current Alcohol Use Disorder ( AUD ) DSM5 criterion base SCID Most recent urine drug test negative Most recent Clinical Institute Withdrawal Assessment Alcohol revise ( CIWAAr ) score less equal 8 Heart rate le equal 100 two separate measurement , assess CIWAAr score less equal 8 Female subject must non childbearing potential define least one follow criterion : ) Females 4565 year old , menopausal , define follow : ) Females 4555 year old : consider menopausal satisfy follow three requirement screen : 1 ) amenorrhea , define absence menstruation previous 12 month ; 2 ) negative urine pregnancy test ; 3 ) serum FSH level within laboratory reference range postmenopausal female . ii ) Females 5665 year old : consider menopausal amenorrhea , define absence menstruation previous 12 month screen . OR b ) Females 2165 year old , documented hysterectomy and/or bilateral oophorectomy . All female subject ( include female tubal ligation females NOT documented hysterectomy ) consider childbearing potential . Male subject must use one follow method contraception first dose study medication 28 day dose ( give unknown whether effect drug cause birth defect ) : 1 . Abstinence . 2 . A condom AND one following : Vasectomy 6 month . Female partner meet one follow condition : 1 . Has tubal ligation , hysterectomy , bilateral oophorectomy ; 2 . Is post menopausal ; 3 . Uses one follow form contraception : Copper hormonal contain IUD ; Spermicidal foam/gel/film/cream/suppository ; Diaphragm spermicide ; Oral contraceptive ; Injectable progesterone ; Subdermal implant . EXCLUSION CRITERIA : Current clinical diagnosis substance use disorder ( alcohol and/or nicotine ) Lifetime clinical diagnosis schizophrenia bipolar disorder EKG QTc &gt; 450 msec determine either Bazett Fridericia formulas use QTc value long duration . BMI le equal 18.5 kg/M ( 2 ) anorexia BMI great equal 40 kg/m ( 2 ) History epilepsy and/or seizures Most recent blood test show creatinine great equal 2 mg/dL , AST ALT &gt; 3 time upper normal limit , hemoglobin &lt; 10.5 g/dl Subjects diabetes and/or treat drug glucose lower property sulfonylurea , insulin , metformin , thiazolidinediones ( TZD ) , Dipeptidyl peptidase4 ( DPP4 ) inhibitor , Glucagonlike peptide1 ( GLP1 ) agonists ( due glucoselowering property PF05190457 observe healthy volunteer ) Exclusionary Medications : A. Naltrexone , acamprosate , alcohol dehydrogenase inhibitor , topiramate , gabapentin , ondansetron , benzodiazepine , betablockers , H2blockers , alpha1 blocker , baclofen , drug know prolong QTc interval barbiturates well hormone replacement therapy ; medication dietary/herbal supplement ( like St. John 's wort ) interact Cytochrome P450 3A4 . Patients take medication may enrol study potentially interacting medication stop period least 5 halflives interact medication PF05190457 administration . Unable pas finger rub hear test Vision unable correct ( Snellen ) 20/100 Clinicallysignificant history motion car sickness , history vestibular disorder Any reason clinical condition PI MAI consider unsafe possible participant participate study EXCLUSION CRITERIA FOR fMRI ONLY : Have contraindication brain fMRI , determine NIAAA MRI Safety screen form ( conduct 14AA0181 Screening Protocol ) Colorblindness ( would prevent subject complete Stroop task ) use Ishihara Test Color Deficiency , Concise Edition , 2014 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 9, 2017</verification_date>
	<keyword>Alcohol Consumption</keyword>
	<keyword>Alcohol Treatment</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Ghrelin</keyword>
	<keyword>Ghrelin Antagonism</keyword>
</DOC>